METTL3 and hepatocellular carcinoma: As noted before, METTL3-m6A-EGFR-axis was responsible for acquired resistant to lenvatinib, and the particular METTL3 inhibitor STM2457 amplified tumor response to lenvatinib in HCC animal models via increasing cell apoptosis 40.